90409-78-2|Polifeprosan 20|4,4'-(propane-1,3-diylbis(oxy))dibenzoic acid compound with decanedioic acid (11)|-范德生物科技公司

Polifeprosan 20

NMR下载 COA and HPLC MSDS下载
names：
4,4'-(propane-1,3-diylbis(oxy))dibenzoic acid compound with decanedioic acid (11)
CAS号：
90409-78-2
MDL Number：
MF(分子式)： C27H34O10 MW(分子量)： 518.56
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	4,4'-(propane-1,3-diylbis(oxy))dibenzoic acid compound with decanedioic acid (11)
英文别名	Polifeprosan 20; Polifeprosan; Polifeprosanum.
CAS号	90409-78-2
Inchi	InChI=1S/C17H16O6.C10H18O4/c18-16(19)12-2-6-14(7-3-12)22-10-1-11-23-15-8-4-13(5-9-15)17(20)21;11-9(12)7-5-3-1-2-4-6-8-10(13)14/h2-9H,1,10-11H2,(H,18,19)(H,20,21);1-8H2,(H,11,12)(H,13,14)
InchiKey	JVYNJRBSXBYXQB-UHFFFAOYSA-N
分子式 Formula	C27H34O10
分子量 Molecular Weight	518.56
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Polifeprosan 20(CAS:90409-78-2):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Polifeprosan 20 is biodegradable polymeric matrix that can be surgically implanted for the interstitial delivery of drugs, such as BCNU, in the brain.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Kleinberg L. Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy. Patient Prefer Adherence. 2016 Nov 24;10:2397-2406. eCollection 2016. Review. PubMed PMID: 27920506; PubMed Central PMCID: PMC5125766.

[2]Kleinberg L. Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide. Core Evid. 2012;7:115-30. doi: 10.2147/CE.S23244. Epub 2012 Oct 26. PubMed PMID: 23118709; PubMed Central PMCID: PMC3484478.

[3] Glick JA, Graham RS, Voils SA. Candida meningitis post Gliadel wafer placement successfully treated with intrathecal and intravenous amphotericin B. Ann Pharmacother. 2010 Jan;44(1):215-8. doi: 10.1345/aph.1M453. Epub 2009 Dec 22. PubMed PMID: 20028954.

[4] La Rocca RV, Mehdorn HM. Localized BCNU chemotherapy and the multimodal management of malignant glioma. Curr Med Res Opin. 2009 Jan;25(1):149-60. doi: 10.1185/03007990802611935 . Review. PubMed PMID: 19210148.

[5] Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol. 2008 Oct;15(10):2887-93. doi: 10.1245/s10434-008-0048-2. Epub 2008 Jul 18. PubMed PMID: 18636295.

6: Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol. 2007 Feb 1;25(4):399-404. PubMed PMID: 17264335; PubMed Central PMCID: PMC2556256.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开